Wave Life Sciences Ltd. 8-K

What Happened
Wave Life Sciences Ltd. (WVE) filed an 8-K on February 2, 2026, and issued a press release stating it will "accelerate regulatory engagement" now that it has full control of WVE-006, its therapeutic program for Alpha-1 Antitrypsin Deficiency (AATD). The press release was attached to the filing as Exhibit 99.1.

Key Details

• Filing date and disclosure: 8-K filed February 2, 2026 (press release dated the same day).
• Program: WVE-006 is the program referenced, for the indication Alpha-1 Antitrypsin Deficiency (AATD).
• Action announced: Wave said it will accelerate regulatory engagement relating to WVE-006 and stated it has "full control" of the program.
• Disclosure format: The announcement was made via company press release (Exhibit 99.1) incorporated by reference in the 8-K.

Why It Matters
This is a material operational update about Wave's WVE-006 program: the company is publicly stating a change in control and an intention to move more actively on regulatory interactions. For investors, that means management is prioritizing regulatory progress for a specific program (WVE-006/AATD)—watch for follow-up regulatory filings, clinical updates, or guidance that could affect the program’s development timeline and corporate value.